Why U.S. Steelmakers Won't Win From Trump's Tariffs
President Trump’s steel and aluminum tariffs may not result in the intended boom for the U.S. steel industry.
“If the automakers are using less metal, they’re selling less product because of these tariffs, eventually I think it’s going to hurt steel stocks,” said Patrick Sanders, Assistant Managing Editor at U.S. News & World Report.
He pointed out that Bank of America has already downgraded U.S. Steel in light of Trump’s announcement.
The tariffs could also hit employment numbers, said Sanders.
“The last time that we had steel tariffs was in 2003. About 200,000 people lost their jobs. A lot of those were in the auto industry.”
On Thursday, Trump stated he’d slap a 25 percent tax on steel imports and a 10 percent tarriff on aluminum imported into the U.S.
Trump claimed the policy would benefit American industrials, tweeting, “We must protect our country and our workers. Our steel industry is in bad shape.”
Catching you up on what you need to know on April 5, 2022, with Biden's call for a war crimes trial for Putin, another arrest made in the Sacramento mass shooting, NYC rolling out a campaign against Florida’s "Don’t Say Gay" bill, an aluminum shortage potentially affecting beer and cat food cans, and more.
Stocks closed lower on Wall Street Tuesday and bond yields jumped as remarks by a Federal Reserve governor fueled expectations on Wall Street that the central bank is prepared to more aggressively raise interest rates.
Filing your taxes should be easy and straightforward if your documents are together — but what about if you became a new cryptocurrency or retail investor? What if you worked remotely last year, and not in the same state as your employer? What if you received a pandemic stimulus check, or are eligible for the child tax credit? Luis Rivero, CPA and Director of Tax at Taxfyle, joins Closing Bell to discuss what exactly all taxpayers need to know, whether they hold crypto investments, worked out of state, have children, and more.
Two years after the pandemic began, vaccines are widespread, but COVID-19 treatments aren't as plentiful. RedHill Biopharma is working to change that with its easy-to-take coronavirus treatments — which come in pill form and treat cases ranging from mild to severe. Guy Goldberg, Chief Business Officer at RedHill Biopharma, joins Closing Bell to discuss the company's two COVID-19 treatments in trial, pricing once the drugs are widely available, the company's latest earnings results, and more.
